Supplementary appendix

This appendix formed part of the original submission and supplied by the authors.

Study Title: “A prospective observational study of community-acquired bacterial bloodstream infections in Metro Manila, the Philippines”

Running title: Community-acquired bacterial bloodstream infections in Manila

Contents:

Appendix 1.
Sample collection and diagnostic tests to be perform per protocol

Appendix 2.
Table S1. Final laboratory and clinical confirmed diagnosis when more than two pathogens were identified by study tests

Appendix 3.
Table S2. Characteristics of patients enrolled as the dengue control (Clinical diagnosed with dengue fever)

Appendix 4.
Table S3. Physical and clinical signs of enrolled patients and the association with positive results of blood culture

Appendix 5.
Table S4. The blood culture volume and blood culture positivity
Appendix 1.

Sample collection and diagnostic tests to be perform per protocol

Samples collected by the study
We obtained blood samples (Acute and Convalescent) from enrolled patients during the enrollment. The blood volume is shown below according to the age.

Acute phase sample
Adult and children over 6 years:
Total 10–19 ml (6-14 ml for bacterial culture divided equally between two blood culture bottles; 1 ml for complete blood count (CBC), 2 mL for renal function and liver enzymes; 2 mL EDTA research sample for polymerase chain reaction (PCR) and other tests.)
For children aged between 3 and 6 years:
Total 8–15 ml (4–10 ml for bacterial culture divided equally between two blood culture bottles (or in one blood culture bottle if volume < 6 mL); 1 ml for CBC, 2 mL for renal function and liver enzymes; 2 mL EDTA research sample for PCR and other tests.
For children aged between 1 and 2 years:
Total 6–11 ml: 2–6 ml for bacterial culture in one blood culture bottle, 1 ml for CBC, 2 mL for renal function and liver enzymes; 2 mL EDTA research sample for PCR and other tests.

Convalescent samples
We obtained an additional 2 mL EDTA research blood sample drawn for convalescent serology between 7 and 10 days of after enrollment or on the day of discharge if sooner.

The research blood sample were taken into an EDTA tube and centrifuged within 3 hours at 1000 g for 10 minutes. Then it was divided into buffy coat and plasma in separate tubes. Plasma was divided into two tubes. These were stored at −80°C freezer.

A urine sample was also collected from each patient for microscopy and culture when relevant; an assay of antimicrobial activity; and storage at −80°C

DNA from blood samples
One plasma tube was centrifuged at 21,000 g for 10 min. Then DNA extracted from the plasma pellet using QIAamp DNA Mini Kit (QIAGEN Inc., Valencia, CA, USA). DNA was also extracted from buffy coat samples using the QIAamp DNA Mini Kit (QIAGEN Inc., Valencia, CA, USA).
**Diagnostic test to be performed in this study**

A set of reference diagnostic tests were performed for each patient according to clinical presentation and the flow was shown in Figure1.

Figure S1: Flow of diagnostic tests to be performed in this study

| All patients | Sample requested: Blood, Urine |
|--------------|-------------------------------|
| **Blood culture** | complete blood count (CBC), blood chemistry tests, CRP, PCT |
| | Dengue RDT (NS1, IgM), Dengue RT-PCR |
| | Leptospirosis IgM ELISA (Patoc-IgM ELISA) |

| **Suspect Dengue** | Dengue IgM ELISA in-house |
| **Suspect Leptospirosis** | Blood culture with specific media (Korthof’s medium) |
| | And |
| | Blood (plasma) LAMP (screening) and real-time PCR (confirmation) |

| **Suspect Diphtheria** | Throat or nasopharynx swab |
| | Culture with selective media (Hoyle’s agar with potassium tellurite) |
| | And |
| | Toxic gene PCR of throat or the swab samples |

| **Suspect Meningococcus** | Blood (buffy coat) PCR |
| **Suspect Pneumonia** | Chest X-ray |
| | Sputum culture (if available) |

| **Suspect urinary tract infection** | Urine culture (if available) |

**Diagnostic tests to be performed in every case**

**Complete blood count**

**Blood culture**

- Dengue Rapid diagnostic test (RDT) (Dengue Duo, NS1, IgM and IgG, Standard Diagnostics, South Korea).
- Dengue reverse transcription-polymerase chain reaction (RT-PCR)
- Rapidchip PCT kit (Sekisui Medical, Japan)
- Alere Afinion CRP kit with Alere Afinion AS100 Analyzer (Alere Medical, Japan)
- Patoc-IgM enzyme linked immunosorbent assay (in-house ELISA) (Samples during the admission and convalescent phase)

**Diagnostic tests to be performed in cases suspected with dengue**

- Dengue IgM in-house ELISA

**Diagnostic tests to be performed in cases suspected with leptospirosis**

- Culture with Korthof’s medium
- LAMP and real-time PCR

Community-acquired bacterial bloodstream infections in Manila
Supplementary appendix
Diagnostic tests to be performed in cases suspected with diphtheria
Throat or nasopharynx swab is taken from the suspected patient.
5% sheep blood agar and selective Hoyle’s agar with potassium tellurite (Oxoid, Cheshire, England)
Tox-gene PCR of throat or nasopharynx swab samples (Direct toxin gene detection on the throat swabs.)

Diagnostic tests to be performed in cases suspected with meningococcal disease
Blood (buffy coat) PCR

Diagnostic tests to be performed in cases suspected with pneumonia
Chest X-ray
Sputum culture

Diagnostic tests to be performed in cases suspected with urinary tract infection
Urine culture

Diagnostic tests to be performed when an attending physician requests
Other microbiological tests, blood urea nitrogen, creatinine, AST, ALT

**Laboratory procedure of each test**

**Blood culture**
Trained nurse collected blood from a single peripheral site. We performed blood culture processing, isolate identification, and antimicrobial susceptibility testing (AST) at the SLH-Nagasaki collaborative laboratory in SLH. Blood was inoculated into two aerobic blood culture bottles of automated blood culture systems. Only aerobic culture was performed but not anaerobic culture. We used BacT/ALERT automated system (Organon-Teknika Corp., Durham, N.C.) between Jun 2015 and November 2017. The blood culture bottles were BacT/ALERT FA Plus adult bottle for patients aged 7 years or more and BacT/ALERT PF Plus pediatric bottle for patients aged under 7 years. Since December 2017, we have used BACTEC 9050 system (Becton Deckinson, Franklin Lakes, NJ). BACTEC aerobic bottle for patients aged 7 years or more and BACTEC Peds Plus for patients aged under 7 years. Blood culture bottles were assessed by comparing the weight before and after inoculation. All culture bottles were incubated for 5 days. Bottles flagging positive were sub-cultured in Columbia sheep blood, chocolate, and MacConkey’s agars. The isolate identification was performed by MALDI Biotyper (Bruker Daltonics, Bremen, Germany) with additional standard microbiological techniques and VITEC2 compact (bioMérieux, France). Optochin susceptibility test was used to distinguish *Streptococcus pneumoniae* from other alpha hemolytic streptococcus. Organisms which were considered contaminated by physician and microbiologist were excluded from the analysis. These organisms are frequently associated with contamination including coagulase negative staphylococci, viridans group streptococci, *Corynebacterium* spp., *Bacillus* spp., *Micrococcus* spp. and *Propionibacterium* spp. AST was done by modified Kirby-Bauer disc

Community-acquired bacterial bloodstream infections in Manila
Supplementary appendix
diffusion method using Sensi-Disc (BD: Becton, Dickinson and Company, USA) with additional VITEC2 compact according to the Clinical and Laboratory Standards Institute guidelines[1]. Other clinical samples such as sputum and urine were processed by standard microbiological methods. If MALDI-TOF identification was *Burkholderia thailandensis* or *B. pseudomallei*, *Salmonella enterica* serotype Paratyphi A, or *S. enterica* serotype Typhi, DNA was extracted using QIAamp DNA Blood Mini Kit following the manufacturer’s instructions and PCR identification was applied using primers described elsewhere [2–4]. We also performed *Salmonella* somatic and flagellar serotyping antisera tests to confirm *S. Paratyphi A* and *S. Typhi* according to the manufacturer's instructions; (Denka Sieken, Japan).

**Diagnostic tests for dengue**

**Dengue RDT**

Dengue RDTs were performed according to the manufacturers' instructions using plasma sample. Dengue Rapid diagnostic test (RDT) (Dengue Duo, NS1, IgM and IgG, Standard Diagnostics, South Korea).

**Dengue virus Conventional RT-PCR [5]**

RNAs were extracted from 100 μL plasma portion by using ISOGEN II (Wako, Japan) according to the manufacturer’s protocol. The generic pan-dengue primers used, which targeted th e 3’ noncoding region of dengue viruses, were pan-dengue forward (5’- TCAATATGCTGAAACGCGCGAGAAACCG-3’) and pan-dengue reverse (5’- GAAAACTTTTCTTGTACCACGGGACTAA -3’). Conventional RT-PCR reactions were performed on the Veriti Thermal Cycler (Applied Biosystems, US) using PrimeScript One Step RT-PCR Kit Ver.2 (Takara, Japan). Cycling conditions were the following: 50°C for 30 min and 94°C for 2 min then 30 cycles of 94°C for 30 sec, 56°C for 30 sec and 72°C for 1 min. Capillary electrophoresis system, MultiNA (Shimadzu Corporation, Japan), was used to detect the PCR product.

**In-house anti-dengue IgM capture ELISA [6]**

Plasma samples were sent to Research Biotechnology Division, St Luke’s Medical Center. In-house anti-dengue IgM ELISA was performed. The samples were diluted in 1:100. Optical densities were determined based on absorbance readings, and then the positive - negative ratio (P/N ratio) was calculated. A cut-off value of 2.00 was used based on the result of the negative control population.

**Leptospirosis diagnostic test**

**Whole cell-based IgM ELISA (Patoc-IgM ELISA)**

The *Leptospira biflexa* serovar Patoc antigen coating plate was prepared according to the WHO guidance [7]. Excess binding sites of the well were blocked with 200 μl per well of 20 mg/ml of BSA in 20 mM Tris, 150 mM NaCl, 0.05% Tween 20, pH 7.5 (TBST) for 1.5 h at room temperature (RT), after which the BSA solution was removed. The plate was rinsed six times with 200 μl per
well of distilled water, and then blocked with 200 µl per well of 20 mg/ml of BSA in TBST for 1.5 h at RT. The plate was then rinsed three times with 300 µl per well of TBST. 50 µl of patient plasma samples diluted 400-fold with ELISA buffer were added in a total volume of 50 µl per well and incubated for 1.5 h at RT. The plasma was then rinsed four times with 200 µl per well of TBST then replaced with 50 µl per well of peroxidase-conjugated goat anti-human IgM solution (QED Bioscience) diluted 5000-fold with ELISA buffer and then incubated for 1 h at RT. The goat anti-human IgM solution was then rinsed out as above. Finally, 50 µl of o-phenylenediamine dihydrochloride solution (OPD tablet (Sigma) in 6 ml distilled, deionized water containing 0.02% hydrogen peroxide) was added and settled for 2 min, and the reaction was stopped by adding 50 µl per well of 1M sulfuric acid solution. Absorbance at 492 nm of each well was quantitated in a microtiter-plate reader (Biotek Epoch- Microplate spectrophotometer / microplate reader). The mean±3 standard deviation (SD) value of blood donor controls were defined as the cut-off limit for a positive result. Positive for Leptospirosis Patoc-IgM ELISA were defined as positive results of Patoc-IgM ELISA with diluted 400-fold plasma of admission samples or convalescent samples.

Leptospirosis blood culture
Blood culture was performed using Korthof’s medium. After the sample collection, 1–2 drops of blood were put into Korthof’s medium and cultivated at 30°C up to 13 weeks. The cultures were examined weekly by dark-field microscopy. Positive cultures were identified by MAT and PCR.

Leptospirosis blood (plasma) PCR
Extracted DNA from plasma samples were used for PCR of leptospirosis. Lepto-rrs LAMP was used as screening when the patients were suspected with leptospirosis. When the Lepto-rrs LAMP was positive, we performed real time PCR as confirmation. Patients with positive for both PCR tests were determined as PCR positive leptospirosis.

Lepto-rrs LAMP
Lepto-rrs LAMP was performed using previously described primers and conditions [8]. The reaction mixture (25 µl) for the Lepto-rrs LAMP contained 1.6 µM each primer (FIP, 5’-TAG TTTCAAGTGCAGGCTGCGAGGCGGACATGTAAGTCAGG-3’; BIP, 5’-GGAGTTTGGGAGA GGCAAGTGGGCACCCTGGGTCCCTCCA-3’; LF, 5’-GTTGAGCCGCCAGTTTTTCAC-3’; LB, 5’-AATTCCAGTGATGCGGGTGA-3’) and 0.2 µM other primers (F3, 5’-TCATTGGGCGGTAA AGGGTG-3’; B3, 5’-AGTTTTCAGCGCAGATACC-3’), in addition to 20 mM Tris-HCl (pH 8.8), 10 mM KCl, 8 mM MgSO₄, 10 mM (NH₄)₂SO₄, 0.1% Tween 20, 0.8 M betaine, 0.72 mM each deoxynucleotide triphosphate, 1 µl of a fluorescent detection reagent (Eiken Chemical Company, Tochigi, Japan), 8 U of Bst DNA polymerase (Lucigen, Middleton, WI), and

Community-acquired bacterial bloodstream infections in Manila
Supplementary appendix
2 μl of DNA template. DNA templates were heated to 95°C for 2 min, followed by rapid cooling on ice before addition to the LAMP reaction mixture. LAMP reactions were performed at 65°C for 60 min, followed by termination at 95°C for 5 min using Veriti Thermal Cycler (Applied Biosystems, US). Positive and negative results were distinguished by UV fluorescence.

**Leptospirosis real time PCR blood (plasma)**

Primers and a probe that target leptospiral 16S ribosomal RNA gene (rrs) were designed for a real-time PCR assay {F3C (400 nM), 5’-TCATTGGCGTAAGGTTG-3’; B3C (600 nM), 5’-TCAGTTTAGCCAGCAAGTC-3’; Probe (250 nM), 56-FAM/AGAGGCAAG/ZEN/TGGAGTTCCAGGTG/BHQ}. Real time PCR reactions were performed on the StepOne (Applied Biosystems, US) using the One Step PrimeScript RT-PCR Kit (Takara, Japan). Results were evaluated on the linear scale with slope correction and a threshold of 0.05. A positive result was considered any exponential curve with a cycle threshold (CT) prior to cycle 35. Cycling conditions were the following: 50°C for 2 min and 95°C for 20 sec then 45 cycles of 95°C for 1 sec and 60°C for 30 sec.

**Diagnostic test for diphtheria**

Laboratory-confirmed cases were defined as a patient with a positive result of culture for *C. diphtheriae* and/or a tox-gene PCR positive result from throat or nasopharynx swab samples. Throat or nasopharynx swab specimens were taken at the time of admission from all patients with clinically suspected diphtheria. Brain heart infusion (BHI) broth was used as transport medium. The swabs were inoculated to 5% sheep blood agar and selective Hoyle’s agar with potassium tellurite (Oxoid, Cheshire, England). Black suspect colonies on Hoyle’s agar plate which were Gram-positive bacilli were identified using MALDI Biotyper (Bruker Daltonics, Bremen, Germany). The Minimum Inhibitory Concentrations (MICs) of penicillin G and erythromycin were determined by E-test strips according to manufacturer’s instruction (bioMérieux, Lyon, France). We assessed the toxigenicity of the identified isolates by PCR that detects the tox gene using a published method [9]. Direct toxin gene detection was also performed on the throat swabs. DNA was extracted from the 100 μL aliquot of the BHI transport broth using a QIAamp DNA Blood Mini Kit following manufacturer’s instruction (QIAGEN, Hilden, Germany).

**Diagnostic tests for meningococcal disease [10,11]**

The genes can be targeted in *Neisseria meningitidis* species-specific assays, *ctrA* and *sodC*. The capsule transport to cell surface gene, *ctrA*, is highly conserved among isolates responsible for invasive meningococcal infections and has been used in both real-time and conventional PCR to

Community-acquired bacterial bloodstream infections in Manila

Supplementary appendix
detect *N. meningitidis*. Primers of *ctrA* F753 (5′-GCTGCAGTGGTGTACAA-3′) and R (5′-TTGTCGGATTGCAACTA-3′). Extracted DNA from buffy coat was used for the *ctrA* PCR to detect *N. meningitidis*. Conventional PCR reactions were performed on the Veriti Thermal Cycler (Applied Biosystems, US) using TaKaRa Ex Taq Hot start Version (Takara, Japan). Cycling conditions were the following: 94°C for 2 min then 35 cycles of 94°C for 30 sec, 56°C for 30 sec and 72°C for 1 min. Capillary electrophoresis system, MultiNA (Shimadzu Corporation, Japan), was used to detect the PCR product. Capsular group determination was performed using conventional PCR. The sequences shown in Table 2 were the primers used following the standardized protocol by the World Health Organization & Centers for Disease Control and Prevention (2011). The presence of the target capsular gene determines the corresponding capsular group of the *N. meningitidis* isolate. Conventional serogrouping PCR assay for genotyping for serogroup was performed using extracted DNA from blood buffy coat samples or isolates when blood PCR or blood culture was positive following the WHO manuals [10]. Because preliminary analysis showed serogroup B and Y were common in Manila, we used the primers of serogroup B (*synD*) and Y(*synF*).

**Diagnostic tests of X-ray**

If pneumonia was suspected, Chest X-ray was ordered by an attending physician. The X-ray was assessed by both radiologist and the physician by blind method. They were requested to choose three categories namely, “not pneumonia”, “possible pneumonia”, and “highly suspected pneumonia”. If both the radiologist and the physician chose “highly suspected pneumonia”, we defined the patients as X-ray confirmed pneumonia.

**CBC, Procalcitonin (PCT), C Reactive Protein (CRP)**

CBC parameters were evaluated using an automated hematology analyzer (Sysmex XN-1000, Sysmex, Kobe, Japan). The Rapidchip PCT kit (Sekisui Medical, Japan) was used to measure PCT. The detection of PCT was based on immunochromatography technique using Quantitative Immunoassay Analyzer (Sekisui Medical, Japan). The Alere Afinion CRP kit with Alere Afinion AS100 Analyzer (Alere Medical, Japan) was used to measure CRP. Tests require 120 µl and 1.5 µl of either serum or whole blood and have a detection range of 0.2-10 ng/ml and 5-160 mg/L, respectively.

**Analysis of Staphylococcus aureus**

Laboratory test for MRSA was done by the cefoxitin disk diffusion test. Detection of inducible clindamycin resistance was by the disc approximation D-zone test. In addition, PCR and multiplex PCR of the 16S rDNA for *S. aureus, meca* gene, PVL(*lukF-lukS*) and SCCmec types were performed on all *S. aureus* strains [12,13]. SCCmec types (type I, IA, II, III, IV, IVA) were determined with the multiplex PCR. These types are commonly identified in South Asian countries.

Community-acquired bacterial bloodstream infections in Manila

Supplementary appendix
DNA extracted from isolates was stored at −20°C using a DNA extraction kit (Wizard Genomic DNA Purification Kit; Promega) and transported to Nagasaki, Japan for multilocus sequence typing (MLST) as described by Bolt et al [14]. The MLST of *S. aureus* uses seven housekeeping genes combinations of *arcC, aroE, glpF, gmk pta, tpi* and *ygiL*. Sequence types (STs) were assigned by the PubMLST database and added to this database (https://pubmlst.org/). We generated a phylogenetic tree by using Molecular Evolutionary Genetics Analysis (MEGA) software version MEGA 7.0.26 (https://www.megasoftware.net/).

**Flow of making final diagnosis:**

In case more than two laboratory tests were positive, final diagnosis was made following the Supplementary table 1. The following case definitions were used. A bacteremia group was defined as positive blood culture if organisms were not considered contaminated. A proven dengue virus infection was defined as positive result of NS1 RDT or dengue RT-PCR. A probable dengue virus infection was defined as (Dengue RDT IgM positive or Dengue IgM-ELISA positive) and all other tests were negative. A proven leptospirosis are defined i) PCR or Culture positive or ii) seroconversion of Patoc-IgM ELISA. A probable leptospirosis was defined as positive results of Patoc-IgM ELISA of acute phase sample. Diphtheria infection was defined as culture positive or PCR positive of throat/nasopharynx swab. Blood culture negative meningococcal infection was defined as a negative result of blood culture and positive results of blood PCR. X-ray confirmed pneumonia group was defined as a negative result of blood culture and chest X ray showed highly suspect pneumonia. A severe skin infection was defined as a negative result of blood culture and cellulitis or possible abscess formation of the deep dermis and subcutaneous tissue.

**Reference**

1. Clinical & Laboratory Standards Institute (CLSI). M100Ed31 | Performance Standards for Antimicrobial Susceptibility Testing, 31st Edition. In: Clinical & Laboratory Standards Institute (CLSI) [Internet]. 2013 [cited 31 Mar 2021]. Available: https://clsi.org/standards/products/microbiology/documents/m100/
2. Ravan H, Yazdanparast R. Loop region-specific oligonucleotide probes for loop-mediated isothermal amplification-enzyme-linked immunosorbent assay truly minimize the instrument needed for detection process. Anal Biochem. 2013;439: 102–108. doi:10.1016/j.ab.2013.04.014
3. Fan F, Du P, Kan B, Yan M. The Development and Evaluation of a Loop-Mediated Isothermal Amplification Method for the Rapid Detection of Salmonella enterica serovar Typhi. PLoS One. 2015;10: e0124507. doi:10.1371/journal.pone.0124507
4. Tuanyok A, Auerbach RK, Brettin TS, Bruce DC, Munk AC, Detter JC, et al. A horizontal gene
transfer event defines two distinct groups within Burkholderia pseudomallei that have dissimilar geographic distributions. J Bacteriol. 2007;189: 9044–9049. doi:10.1128/JB.01264-07

5. National Institute of Infectious Disease in Japan. Laboratory manuals for pathogen detection, dengue fever. [cited 31 Mar 2021]. Available: https://www.niid.go.jp/niid/en/examination.html

6. Bundo K, Igarashi A. Antibody-capture ELISA for detection of immunoglobulin M antibodies in sera from Japanese encephalitis and dengue hemorrhagic fever patients. J Virol Methods. 1985;11: 15–22. doi:10.1016/0166-0934(85)90120-x

7. World Health Organization. Human leptospirosis : guidance for diagnosis, surveillance and control. 2003. Available: https://apps.who.int/iris/handle/10665/42667

8. Koizumi N, Nakajima C, Harunari T, Tanikawa T, Tokiwa T, Uchimura E, et al. A new loop-mediated isothermal amplification method for rapid, simple, and sensitive detection of Leptospira spp. in urine. J Clin Microbiol. 2012;50: 2072–2074. doi:10.1128/JCM.00481-12

9. Nakao H, Popovic T. Development of a direct PCR assay for detection of the diphtheria toxin gene. J Clin Microbiol. 1997;35: 1651–1655. doi:10.1128/JCM.35.7.1651-1655.1997

10. World Health Organization, Centers for Disease Control and Prevention (U.S.). Laboratory methods for the diagnosis of meningitis caused by neisseria meningitidis, streptococcus pneumoniae, and haemophilus influenzae : WHO manual. 2nd ed. 2011. Available: https://apps.who.int/iris/handle/10665/70765

11. National Institute of Infectious Disease in Japan. Laboratory manuals for pathogen detection, Neisseria meningitidis. [cited 31 Mar 2021]. Available: https://www.niid.go.jp/niid/en/examination/9493-labmanual-en.html

12. Oliveira DC, de Lencastre H. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2002;46: 2155–2161. doi:10.1128/aac.46.7.2155-2161.2002

13. Lina G, Piémont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis. 1999;29: 1128–1132. doi:10.1086/313461

14. Bolt F, Cassiday P, Tondella ML, Dezoysa A, Efstratiou A, Sing A, et al. Multilocus sequence typing identifies evidence for recombination and two distinct lineages of Corynebacterium

Community-acquired bacterial bloodstream infections in Manila
Supplementary appendix
diphtheriae. J Clin Microbiol. 2010;48: 4177–4185. doi:10.1128/JCM.00274-10
**Appendix 2.**

**Table S1. Final laboratory and clinical confirmed diagnosis when more than two pathogens were identified by study tests**

| Laboratory test (N=) | Total number of detected | Blood culture (+) | Dengue NS1 (+) or RT-PCR (+) | Dengue {NS1 (-) and RT-PCR (-) or ELISA IgM (+)} | Lepto PCR (+) or Culture (+) or Lepto IgM seroconversion | Lepto {PCR (+) or Culture (+) and IgM (+)} | X ray confirmed pneumonia | Diphtheria PCR (+) or culture (+) | Meningococcus PCR (+) | Severe Skin infection (+) |
|---------------------|--------------------------|------------------|-----------------------------|---------------------------------|-------------------------------------------------|---------------------------------|--------------------------|---------------------------|------------------|-------------------------|
| Blood culture (+)   | 77                       |                  | B (0)                       | B (1)                           | B (2)                                            | B (3)                                           | B (8)                    | N (0)                     | B (8)            | B (15)                  |
| Dengue NS1 (+) or RT-PCR (+) | 79                   |                  | D (0)                       | N (3)                           | D (2)                                            | D (2)                                           | Diph (0)                | M (0)                     | N (0)            |
| Dengue {NS1 (-) and RT-PCR (-)} and {RDT IgM (+) or ELISA IgM (+)} | 80                   |                  | L (9)                       | N (5)                           | N (5)                                            | Diph (2)                                        | M (2)                    | N (3)                     |
| Lepto PCR (+) or Culture (+) or Lepto IgM seroconversion | 97                   |                  | L (0)                       | L (2)                           | N (0)                                            | N (1)                                           | L (0)                    |                           |                  |
| {Lepto PCR (-) or Culture (-)} and IgM (+) | 45                   |                  |                             |                                 |                                                  |                                                 |                          |                           |                  |
| X ray confirmed pneumonia | 86                   |                  |                             |                                 |                                                  |                                                 |                          |                           |                  |
| Diphtheria PCR (+) or culture (+) | 50                   |                  |                             |                                 |                                                  |                                                 |                          |                           |                  |
| Meningococcus PCR (+) | 26                   |                  |                             |                                 |                                                  |                                                 |                          |                           |                  |
| Severe skin infection (+) | 59                   |                  |                             |                                 |                                                  |                                                 |                          |                           |                  |

N: No laboratory diagnosis, B: Bacteremia, D: proven Dengue, D: pD: probable Dengue, L: proven leptospirosis, pL: probable leptospirosis, P: Xray confirmed pneumonia, Diph: Diphtheria, M: Meningococcus, S: Severe skin infection

Community-acquired bacterial bloodstream infections in Manila
Supplementary appendix
### Appendix 3.

#### Table S2. Characteristics of patients enrolled as the dengue control (Clinical diagnosed with dengue fever)

|                          | Clinically diagnosed with Dengue fever (N=257) | %  |
|--------------------------|-----------------------------------------------|----|
| **Enrolled season**      |                                               |    |
| 2015July~2016Jun         | 0                                             | 0  |
| 2016July~2017Jun         | 47                                            | 18.3|
| 2017July~2018Jun         | 98                                            | 38.1|
| 2018July~2019Jun         | 112                                           | 43.6|
| **Dry season (Nov~Jun)** | 180                                           | 70  |
| **Rainy season (July~Oct)**| 77                                           | 30  |
| **Age group**            |                                               |    |
| Under 5                  | 7                                             | 2.7 |
| 6-17y                    | 93                                            | 36.2|
| 18 years and above       | 157                                           | 61.1|
| **Sex**                  |                                               |    |
| Female                   | 99                                            | 38.5|
| Male                      | 158                                           | 61.5|
| **Place of residence (1 missing data)** |            |    |
| Manila City              | 96                                            | 37.4|
| Outside Manila City      | 161                                           | 62.7|
| **Duration of fever (1 missing data)** |       |    |
| <=7 days                 | 247                                           | 96.1|
| >7 days                  | 10                                            | 3.9 |
| **Underlying chronic condition N (%) (1 missing value)** |            |    |
| No                       | 220                                           | 86.3|
| Yes                      | 35                                            | 13.7|
| **Antibiotic use before admission** |          |    |
| No                       | 199                                           | 77  |
| Yes                      | 59                                            | 23  |
| **Referral from other facilities** |                 |    |
| No                       | 179                                           | 69.7|
| Yes                      | 78                                            | 30.4|
| **BT 37> on admission**  |                                               |    |
| No                       | 104                                           | 40.5|
| Yes                      | 153                                           | 59.5|
| **Shock (mean blood pressure < 70)** |            |    |
| No                       | 247                                           | 96.1|
| Yes                      | 10                                            | 3.9 |
| **Glasgow Coma Scale**   |                                               |    |
| >=15                     | 257                                           | 100 |
| <15                      | 0                                             | 0   |
| qSOFA                    |                                               |    |
| <2                       | 249                                           | 96.9|
| >=2                      | 8                                             | 3.1 |
| **WBC× 10⁹/L (19 missing value)** |           |    |
| <15.0                    | 252                                           | 98.1|
| >=15.0                   | 5                                             | 2   |
| **Neutrophils % (18 missing value)** |           |    |
| <80                      | 242                                           | 94.2|
| >=80                     | 15                                            | 5.8 |
| CRP (10> mg/dL)(8missing value) | <10 | 242 | 94.2 |
|--------------------------------|-----|-----|------|
| >=10                          | 15  | 5.8 |
| PCT (0.75> ng/mL)(47 missing value) | <0.75 | 148 | 59.7 |
| >=0.75                        | 100 | 40.3 |
| Blood culture positive        | 0   | 0   |
| Mortality, n (%)              | 0   | 0   |

CRP, C-reactive protein; PCT, procalcitonin; qSOFA, quick Sequential Organ Failure Assessment;
Table S3. Physical and clinical signs of enrolled patients and the association with positive results of blood culture

| Presenting symptoms                  | N. of showing the signs | % / enrolled patients | N. of BC positive | BC positive ratio | P value | Odds ratio (95% confidence interval) |
|--------------------------------------|-------------------------|-----------------------|-------------------|------------------|---------|-------------------------------------|
| Headache                             | 880                     | 66.9%                 | 55                | 6.3              | 0.39    | 1.25 (0.75~2.08)                    |
| Rigor                                | 289                     | 22.0%                 | 19                | 6.6              | 0.56    | 1.17 (0.69~2.01)                    |
| Cough or sputum                      | 734                     | 55.8%                 | 41                | 5.6              | 0.64    | 0.90 (0.56~1.42)                    |
| Dyspnea                              | 559                     | 42.5%                 | 38                | 6.8              | 0.21    | 1.34 (0.85~2.13)                    |
| Bloody diarrhea                      | 50                      | 3.8%                  | 2                 | 4.0              | 0.57    | 0.66 (0.16~2.77)                    |
| Abdominal pain                       | 677                     | 51.5%                 | 45                | 6.7              | 0.21    | 1.35 (0.85~2.15)                    |
| Coma or confusion                    | 70                      | 5.3%                  | 8                 | 11.4             | 0.04    | 2.2 (1.01~4.77)                     |
| Joint pain                           | 654                     | 49.7%                 | 47                | 7.2              | 0.04    | 1.63 (1.02~2.61)                    |
| Rash during illness                  | 341                     | 25.9%                 | 23                | 6.7              | 0.42    | 1.23 (0.74~2.04)                    |
| Wound                                | 236                     | 17.9%                 | 21                | 8.9              | 0.03    | 1.78 (1.06~3.01)                    |
| Sore throat                          | 428                     | 32.5%                 | 24                | 5.6              | 0.79    | 0.93 (0.57~1.53)                    |
| Chest pain                           | 344                     | 26.2%                 | 29                | 8.4              | 0.02    | 1.77 (1.10~2.86)                    |
| Water diarrhea                       | 396                     | 30.1%                 | 16                | 4.0              | 0.07    | 0.59 (0.34~1.04)                    |
| Vomiting or nausea                   | 710                     | 54.0%                 | 33                | 4.7              | 0.04    | 0.62 (0.39~0.98)                    |
| Physical examination by attending physician |                   |                       |                   |                  |         |                                     |
| Anaemia                              | 110                     | 8.4%                  | 7                 | 6.4              | 0.81    | 1.10 (0.49~2.46)                    |
| Jaundice                             | 131                     | 10.0%                 | 10                | 7.6              | 0.36    | 1.38 (0.69~2.75)                    |
| Conjunctival suffusion               | 228                     | 17.3%                 | 9                 | 4.0              | 0.18    | 0.62 (0.30~1.25)                    |
| Rale                                 | 307                     | 23.3%                 | 16                | 5.2              | 0.58    | 0.85 (0.48~1.50)                    |
| Murmur                               | 12                      | 0.9%                  | 2                 | 16.7             | 0.11    | 3.31 (0.71~15.40)                   |
| Abdominal tenderness                 | 458                     | 34.8%                 | 31                | 6.8              | 0.3     | 1.28 (0.80~2.05)                    |
| Hepatomegaly                         | 21                      | 1.6%                  | 4                 | 19.1             | <0.01   | 3.94 (1.29~12.00)                   |
| Costovertebral angle tenderness      | 162                     | 12.3%                 | 14                | 8.6              | 0.11    | 1.64 (0.89~2.99)                    |
| Edema                                | 44                      | 3.3%                  | 6                 | 13.6             | 0.03    | 2.66 (1.09~6.52)                    |
| Skin congestion                      | 87                      | 6.6%                  | 6                 | 6.9              | 0.67    | 1.21 (0.51~2.56)                    |
| Rash                                 | 280                     | 21.3%                 | 18                | 6.4              | 0.60    | 1.16 (0.67~2.00)                    |
| Lymph adenopathy                     | 148                     | 11.3%                 | 5                 | 3.4              | 0.17    | 0.53 (0.21~1.34)                    |
| Joint swelling                       | 20                      | 1.5%                  | 5                 | 25               | <0.01   | 5.66 (2.00~16.01)                   |
| Calf tenderness                      | 169                     | 12.9%                 | 8                 | 4.7              | 0.53    | 0.79 (0.37~1.67)                    |
| Neck stiffness                        | 60                      | 4.6%                  | 8                 | 13.3             | 0.01    | 2.64 (1.21~5.79)                    |
Appendix 5.

Table S4. The blood culture volume and blood culture positivity

Table S4-1. The definition of adequacy for the blood culture volume

|                    | Recommend Volume | Adequate > = 80% | Less adequate 80% - 50% | Underfilled less than 50% |
|--------------------|------------------|------------------|--------------------------|--------------------------|
| over 12 years      | 10ml×2           | >=16ml           | 8ml-15.9ml               | below 8ml                |
| 4-11 years         | 5ml×2            | >=8ml            | 4ml-7.9ml                | below 4 ml               |
| 1-3 years          | 3ml×2            | >=4.8ml          | 2.4ml-4.9ml              | below 2.4 ml             |

Table S4-2. The blood culture positivity and the number of blood culture volume*

|                   | Negative | Positive | BC Positivity | P value |
|--------------------|----------|----------|---------------|---------|
| 1 Bottles          | 211      | 11       | 4.95          | 0.256   |
| 2 Bottle           | 728      | 25       | 3.32          |         |

Table S4-3. The blood culture positivity and the adequacy of the blood volume for blood culture*

|                   | Negative | Positive | BC Positivity | P value |
|--------------------|----------|----------|---------------|---------|
| Adequate >= -20%   | 424      | 14       | 3.2           | 0.601   |
| Less adequate -20% to -50% | 339 | 13       | 3.69          |         |
| Underfilled less than 50% | 176 | 9        | 4.86          |         |

*N=947, 367 missing values due to unavailable to weight the blood culture bottle